Market Closed -
Canadian Securities Exchange
20:59:29 13/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.9
CAD
|
0.00%
|
|
-5.26%
|
-40.79%
|
Fiscal Period: August |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
144
|
30.32
|
15.68
|
57.63
|
117.1
|
218.5
|
Enterprise Value (EV)
1 |
144.6
|
33.09
|
25.75
|
69.72
|
126
|
221.8
|
P/E ratio
|
-12.1
x
|
-0.95
x
|
-5.56
x
|
-12.6
x
|
-23.4
x
|
-238
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,751
x
|
256
x
|
216
x
|
93.8
x
|
139
x
|
6.18
x
|
EV / Revenue
|
1,758
x
|
279
x
|
354
x
|
114
x
|
150
x
|
6.28
x
|
EV / EBITDA
|
-23.2
x
|
-11
x
|
-12
x
|
-18.1
x
|
-38
x
|
217
x
|
EV / FCF
|
82.4
x
|
-9.61
x
|
-5.46
x
|
-121
x
|
-40.9
x
|
-54.9
x
|
FCF Yield
|
1.21%
|
-10.4%
|
-18.3%
|
-0.83%
|
-2.45%
|
-1.82%
|
Price to Book
|
3.45
x
|
23.2
x
|
-11.6
x
|
-15
x
|
8.9
x
|
8.88
x
|
Nbr of stocks (in thousands)
|
94,744
|
94,744
|
84,744
|
84,744
|
94,404
|
114,404
|
Reference price
2 |
1.520
|
0.3200
|
0.1850
|
0.6800
|
1.240
|
1.910
|
Announcement Date
|
31/01/19
|
30/12/19
|
23/12/20
|
24/12/21
|
28/12/22
|
29/12/23
|
Fiscal Period: August |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.0823
|
0.1185
|
0.0727
|
0.6141
|
0.8425
|
35.34
|
EBITDA
1 |
-6.226
|
-2.995
|
-2.15
|
-3.846
|
-3.315
|
1.02
|
EBIT
1 |
-6.235
|
-2.999
|
-2.153
|
-4.472
|
-3.945
|
0.3732
|
Operating Margin
|
-7,579.5%
|
-2,530.49%
|
-2,960.58%
|
-728.21%
|
-468.3%
|
1.06%
|
Earnings before Tax (EBT)
1 |
-6.378
|
-28.56
|
-3.029
|
-4.915
|
-4.995
|
-0.5618
|
Net income
1 |
-6.378
|
-28.53
|
-2.818
|
-4.558
|
-4.727
|
-0.9139
|
Net margin
|
-7,753.26%
|
-24,074.18%
|
-3,873.96%
|
-742.22%
|
-561.1%
|
-2.59%
|
EPS
2 |
-0.1254
|
-0.3366
|
-0.0332
|
-0.0538
|
-0.0531
|
-0.008041
|
Free Cash Flow
1 |
1.756
|
-3.445
|
-4.716
|
-0.5785
|
-3.081
|
-4.044
|
FCF margin
|
2,134.15%
|
-2,906.83%
|
-6,484.51%
|
-94.2%
|
-365.73%
|
-11.44%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/01/19
|
30/12/19
|
23/12/20
|
24/12/21
|
28/12/22
|
29/12/23
|
Fiscal Period: August |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.58
|
2.77
|
10.1
|
12.1
|
8.9
|
3.32
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.0931
x
|
-0.9247
x
|
-4.686
x
|
-3.146
x
|
-2.684
x
|
3.249
x
|
Free Cash Flow
1 |
1.76
|
-3.44
|
-4.72
|
-0.58
|
-3.08
|
-4.04
|
ROE (net income / shareholders' equity)
|
-32.1%
|
-139%
|
1,294%
|
162%
|
-91.4%
|
-4.57%
|
ROA (Net income/ Total Assets)
|
-17.4%
|
-7.48%
|
-17.8%
|
-29.1%
|
-13.1%
|
0.75%
|
Assets
1 |
36.74
|
381.5
|
15.85
|
15.66
|
36
|
-121.9
|
Book Value Per Share
2 |
0.4400
|
0.0100
|
-0.0200
|
-0.0500
|
0.1400
|
0.2100
|
Cash Flow per Share
2 |
0.0300
|
0.0100
|
0
|
0
|
0.0200
|
0.0300
|
Capex
|
-
|
1.08
|
3.7
|
0.01
|
0.22
|
2.01
|
Capex / Sales
|
-
|
915.37%
|
5,086.76%
|
2.2%
|
25.93%
|
5.68%
|
Announcement Date
|
31/01/19
|
30/12/19
|
23/12/20
|
24/12/21
|
28/12/22
|
29/12/23
|
|
1st Jan change
|
Capi.
|
---|
| -40.79% | 77.56M | | +29.98% | 684B | | +30.34% | 568B | | -3.52% | 361B | | +18.59% | 329B | | +4.07% | 284B | | +16.21% | 240B | | +9.66% | 208B | | -6.83% | 200B | | +7.09% | 166B |
Other Pharmaceuticals
|